ATE429929T1 - Verbesserte impfstoffe - Google Patents
Verbesserte impfstoffeInfo
- Publication number
- ATE429929T1 ATE429929T1 AT97946340T AT97946340T ATE429929T1 AT E429929 T1 ATE429929 T1 AT E429929T1 AT 97946340 T AT97946340 T AT 97946340T AT 97946340 T AT97946340 T AT 97946340T AT E429929 T1 ATE429929 T1 AT E429929T1
- Authority
- AT
- Austria
- Prior art keywords
- improved vaccines
- disclosed
- sequence
- coding sequence
- improved
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2959296P | 1996-10-23 | 1996-10-23 | |
| PCT/US1997/019545 WO1998017323A1 (en) | 1996-10-23 | 1997-10-23 | Improved vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429929T1 true ATE429929T1 (de) | 2009-05-15 |
Family
ID=21849843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97946340T ATE429929T1 (de) | 1996-10-23 | 1997-10-23 | Verbesserte impfstoffe |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6228621B1 (de) |
| EP (1) | EP0934083B1 (de) |
| JP (2) | JP2001503260A (de) |
| KR (1) | KR100620481B1 (de) |
| CN (1) | CN1183968C (de) |
| AT (1) | ATE429929T1 (de) |
| AU (1) | AU733719B2 (de) |
| BR (1) | BR9712556A (de) |
| CA (1) | CA2268752A1 (de) |
| DE (1) | DE69739385D1 (de) |
| WO (1) | WO1998017323A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4335099A (en) * | 1998-06-18 | 2000-01-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Surface targeted expression of a modified hepatitis c virus envelope protein |
| US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
| WO2001030382A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Method of inducing and/or enhancing an immune response to tumor antigens |
| GB0009470D0 (en) * | 2000-04-17 | 2000-06-07 | Univ Southampton | Materials and methods relating to immune responses to fusion proteins |
| EP1282702B1 (de) * | 2000-05-10 | 2006-11-29 | Sanofi Pasteur Limited | Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen |
| US7183633B2 (en) * | 2001-03-01 | 2007-02-27 | Analog Devices Inc. | Optical cross-connect system |
| ES2329453T3 (es) * | 2001-05-15 | 2009-11-26 | Ortho Mcneil Janssen Pharm | Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas. |
| WO2004037175A2 (en) * | 2002-10-21 | 2004-05-06 | Mgi Pharma Biologics, Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
| WO2004037284A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
| US20040248798A1 (en) | 2003-02-14 | 2004-12-09 | Peter Sutovsky | Contraceptive methods and compositions related to proteasomal interference |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| CA2504451A1 (en) * | 2004-08-10 | 2006-02-10 | Geron Corporation | Dendritic cell vaccines for treating cancer made from embryonic stem cells |
| CN101437547A (zh) * | 2005-01-20 | 2009-05-20 | 自然科技公司 | 用于遗传免疫的载体和方法 |
| BRPI0817664A2 (pt) * | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| DK2222697T3 (da) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunsuppressive polypeptider og nukleinsyrer |
| KR20110084906A (ko) * | 2008-10-10 | 2011-07-26 | 에라 바이오테크, 에스.에이. | 면역원-특이적 면역보강제로서의 재조합 단백질체들 |
| US20130052221A1 (en) | 2010-02-26 | 2013-02-28 | The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services | Dna-protein vaccination protocols |
| FR2963241B1 (fr) | 2010-07-30 | 2014-10-24 | Inst Rech Developpement Ird | Vaccin contre le paludisme gestationnel |
| GB201507104D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
| EP4276106A3 (de) | 2015-05-13 | 2024-01-24 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Methoden und zusammensetzungen beruhend auf konstruktenenthaltend konservierte elemente zur induktion einer immunantwort |
| US10849985B2 (en) | 2015-05-20 | 2020-12-01 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
| JP2022551467A (ja) * | 2019-10-10 | 2022-12-09 | ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク | 鎮痛性及び麻酔性ペプチド及び他の薬剤 |
| IL307397A (en) * | 2021-04-07 | 2023-12-01 | Univ Leland Stanford Junior | Cell selection methods and related preparations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
| DE69034168T3 (de) | 1989-03-21 | 2013-04-11 | Vical, Inc. | Expression von exogenen Polynukleotidsequenzen in Wirbeltieren |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1992015332A1 (en) * | 1991-03-04 | 1992-09-17 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
| IL101147A (en) * | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| CA2102918C (en) | 1992-03-11 | 2007-05-08 | Joel R. Haynes | Genetic vaccine for immunodeficiency viruses |
| EP0651805B1 (de) * | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method eder intrazellularen bindung von zielgerichteten molekülen |
| JPH08502244A (ja) * | 1992-08-11 | 1996-03-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫調節ペプチド |
| US5633234A (en) * | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| PT681483E (pt) | 1993-01-26 | 2005-11-30 | Wyeth Corp | Composicoes e metodos para distribuicao de material genetico |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| EP0804218A1 (de) | 1994-03-17 | 1997-11-05 | National Jewish Center For Immunology And Respiratory Medicine | Produkt und Verfahren zur Regulierung von Signalübertragungswegen |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| WO1996025953A1 (en) * | 1995-02-24 | 1996-08-29 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
-
1997
- 1997-10-23 AU AU51532/98A patent/AU733719B2/en not_active Ceased
- 1997-10-23 WO PCT/US1997/019545 patent/WO1998017323A1/en not_active Ceased
- 1997-10-23 KR KR1019997003508A patent/KR100620481B1/ko not_active Expired - Fee Related
- 1997-10-23 CN CNB971808562A patent/CN1183968C/zh not_active Expired - Fee Related
- 1997-10-23 BR BR9712556-3A patent/BR9712556A/pt not_active Application Discontinuation
- 1997-10-23 JP JP51972898A patent/JP2001503260A/ja active Pending
- 1997-10-23 EP EP97946340A patent/EP0934083B1/de not_active Expired - Lifetime
- 1997-10-23 DE DE69739385T patent/DE69739385D1/de not_active Expired - Lifetime
- 1997-10-23 CA CA002268752A patent/CA2268752A1/en not_active Abandoned
- 1997-10-23 US US08/957,001 patent/US6228621B1/en not_active Expired - Lifetime
- 1997-10-23 AT AT97946340T patent/ATE429929T1/de not_active IP Right Cessation
-
2000
- 2000-02-02 US US09/496,301 patent/US6248565B1/en not_active Expired - Lifetime
-
2008
- 2008-04-16 JP JP2008107021A patent/JP2008245651A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998017323A1 (en) | 1998-04-30 |
| AU733719B2 (en) | 2001-05-24 |
| BR9712556A (pt) | 1999-10-19 |
| KR20000052711A (ko) | 2000-08-25 |
| US6248565B1 (en) | 2001-06-19 |
| AU5153298A (en) | 1998-05-15 |
| EP0934083A1 (de) | 1999-08-11 |
| JP2008245651A (ja) | 2008-10-16 |
| DE69739385D1 (de) | 2009-06-10 |
| CA2268752A1 (en) | 1998-04-30 |
| EP0934083A4 (de) | 2003-07-23 |
| KR100620481B1 (ko) | 2006-09-06 |
| CN1183968C (zh) | 2005-01-12 |
| EP0934083B1 (de) | 2009-04-29 |
| CN1244807A (zh) | 2000-02-16 |
| US6228621B1 (en) | 2001-05-08 |
| JP2001503260A (ja) | 2001-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE429929T1 (de) | Verbesserte impfstoffe | |
| IL138075A0 (en) | Vaccines, immunotherapeutics and methods for using the same | |
| CY1121353T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις | |
| DK0996717T3 (da) | Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination | |
| NZ335485A (en) | Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof | |
| IS4518A (is) | Nýtt lyfjaform fyrir bóluefni | |
| UA93855C2 (ru) | Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе | |
| CY1105963T1 (el) | Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης | |
| EA199800973A1 (ru) | Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение | |
| AU2003244855A1 (en) | Method to enhance an immune response of nucleic acid vaccination | |
| WO2001064834A8 (en) | Novel nucleic acids and polypeptides | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| ATE346931T1 (de) | Clostridium perfringens impfstoff | |
| BG101038A (bg) | Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък | |
| WO2002024739A3 (en) | Spas-1 cancer antigen | |
| DK1290160T3 (da) | Humane Pellino-polypeptider | |
| FI924222A0 (fi) | Gp75 som ett tumoervaccin mot melanoma. | |
| SG146662A1 (en) | Method | |
| HUP9701586A2 (hu) | Javított inaktivált vakcinák | |
| DE69840326D1 (de) | Steigerung der immunantwort unter verwendung von zielgerichteten molekülen | |
| UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
| ATE386049T1 (de) | Epstein-barr virus type b ctl epitopen | |
| ES2502366T3 (es) | Inducción de inmunidad tumoral por variantes de proteína de unión a folato | |
| WO1999065517A3 (en) | Therapeutic compositions that produce an immune response by altering the antigen | |
| WO2004053092A3 (en) | Human pellino polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |